Jeff Caravella joined Biotheryx as Chief Financial Officer in April 2022. Jeff is responsible for all aspects of the Company’s financial operations, including the development and execution of Biotheryx’s financial and corporate strategy. He previously served as Vice President of Finance at Tango Therapeutics, where he played a key role in the completion of their public offering and designed, built and led the finance and accounting organization. Prior, he held finance roles across commercial, business development and operations functions at other publicly held companies, including Editas Medicine, Charles River Laboratories and Johnson & Johnson. During his 10-year tenure at Johnson and Johnson, Jeff spent two years as the Head of Finance for the J&J Boston Innovation Center, where he led the assessment and strategy for multiple successful business development and licensing deals across the J&J business. Jeff earned his M.B.A. and B.S. from Syracuse University.